7607 Stock Overview
Provides cell therapy products and stem cell culture related services. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
DuoGenic StemCells corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$23.10 |
| 52 Week High | NT$39.40 |
| 52 Week Low | NT$23.00 |
| Beta | 0 |
| 1 Month Change | -17.35% |
| 3 Month Change | -14.44% |
| 1 Year Change | -37.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7607 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | 0.2% | -0.8% | 0.4% |
| 1Y | -37.1% | -26.6% | 27.0% |
Return vs Industry: 7607 underperformed the TW Life Sciences industry which returned -26.6% over the past year.
Return vs Market: 7607 underperformed the TW Market which returned 27% over the past year.
Price Volatility
| 7607 volatility | |
|---|---|
| 7607 Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 5.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 7607's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 7607's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | n/a | www.dgsc.com.tw |
DuoGenic StemCells corporation provides cell therapy products and stem cell culture related services. It also offers cell culture medium, synthesize protein, and stem cell scale up solution; and peripheral blood cell purification cell therapy for Osteoarthritis. The company was founded in 2018 and is based in Taichung City, Taiwan.
DuoGenic StemCells corporation Fundamentals Summary
| 7607 fundamental statistics | |
|---|---|
| Market cap | NT$705.77m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7607 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7607 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7607 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 09:29 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DuoGenic StemCells corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|